Navigation Links
NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
Date:8/15/2011

nsation and $2.4 million of depreciation and amortization), and $21.1 million or $0.27 per share (including $6.7 million of non-cash equity-based compensation, $4.6  million of depreciation and amortization, $1.0 million of non-cash expenses related to the Series E Convertible Redeemable Preferred Stock, $0.9 million of non-cash related in-process research and development expenses, and $0.6 million of non-cash charitable contributions), respectively. Net losses attributable to our controlling interests for the three and six months ended June 30, 2010 were $5.4 million, or $0.11 per share (including $2.3 million of non-cash equity-based compensation and $0.7 million of depreciation and amortization), and $10.1 million, or $0.23 per share (including $4.3 million of non-cash equity-based compensation and $1.5 million of depreciation and amortization), respectively.

The Company invested $5.2 million in capital expenditures during the first six months of 2011, primarily related to the construction of a new pharmaceutical manufacturing facility for its majority-owned subsidiary, Suzhou Erye Pharmaceutical Co., Ltd.

As of June 30, 2011, the Company had cash, cash equivalents and restricted cash of $9.7 million. On July 22, 2011, NeoStem completed a public offering of units raising gross proceeds of $16.5 million which strengthens the Company's cash balance for future operations.

Since the acquisition of PCT, NeoStem has continued to make great progress in its mission to leverage the Company's core competencies and bring new cell based therapeutics to the marketplace, to transition to a developer of its own cell therapies and support the growth of PCT as a premier service provider to attract world-renowned clients and therapeutics partners. The recent capital raise to support this mission and pending acquisition of Amorcyte with a Phase II asset for AMI represent tangible evidence of its achievements. The Company sees the start of the Phase II A
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
2. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
3. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
5. NeoStem Announces Warrant Exercise by Principal Shareholder
6. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
7. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
8. NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
9. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
10. NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
11. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Tasly Pharmaceuticals, Inc., ... modernize medicine, announced today the launch of Deepure. ... developed to address men and women concerned with ... vibrant into old age while helping keep their ... condition-specific, whole-food and herb-based formulas, namely, ProHeart PLUS, ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the markets ... , Russia , ... (BRIC) will see robust expansion as these economies expand ... procedures. Although revenues will be somewhat impeded by poor ... approval times and demand for low-cost products, the market ...
(Date:9/30/2014)... 2014   Easy Breathe , the fastest growing ... that it now offers the revolutionary AirSense ... first sleep apnea therapy devices with internal cellular modems.  ... track and share real-time data on each user,s quality ... therapy.  In addition, the internal modem allows the CPAP ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... American Oriental Bioengineering, Inc. (NYSE: AOB ... dedicated to improving healthcare through the development, manufacture ... and over-the-counter ("OTC") products, today announced that its ... and Chief Financial Officer, Ms. Lily Li were ...
... Jan. 25, 2011 Reportlinker.com announces that ... in its catalogue: Brand ... small molecule brand erosion post-patent expiry ... IntroductionPharma is facing slowing sales growth ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2Reportlinker Adds Brand Erosion Post-Patent Expiry - An analysis of small molecule brand erosion post-patent expiry 2
(Date:10/1/2014)... has shown that more than 80 per cent of ... The study found that medicines called ,JAK inhibitors, halted ... that is present in more than 80 per cent ... or are in clinical trials, for diseases including rheumatoid ... cancer is the second-most common cancer in Australia with ...
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... findings reported at symposium on gastrointestinal cancers , , THURSDAY, ... zeroed in on a biomarker that could detect colorectal ... invasive and more accurate way than existing blood tests. ... also differentiate between early- and late-stage disease, the researchers ...
... ZYTO Corp. (Pink Sheets:,ZYTC) has announced the appointment of ... Howard as C.F.O., The internal appointments come as ... Dr. Vaughn R. Cook, company founder, president and,C.E.O. Howard ... the,financial responsibilities., Howard joined ZYTO in April of ...
... is a,statement by Blue Shield of California CEO Bruce Bodaken ... universal coverage, I,m disappointed that we,did not clear this hurdle ... make perfection the enemy of the good. This bill should ... We have waited too long to make health coverage for ...
... Jan. 23 InterMune, Inc.,(Nasdaq: ITMN ) today ... InterMune, will present at the 2008 Wachovia Healthcare,Conference in ... To access a live audio webcast of the ... the investor relations page of InterMune,s,corporate website at ...
... RARITAN, N.J., Jan. 23 Johnson & Johnson,Pharmaceutical ... a New Drug Application (NDA) to the U.S. ... release (IR),tablets, an investigational oral analgesic for the ... to the American Pain Foundation, more than 25 ...
... treatments to blame, study finds , , WEDNESDAY, Jan. 23 ... to treat people with peripheral arterial disease (PAD) than ... finds. , Both PAD (blocked abdomen and leg arteries) ... same methods, including medication, surgery and endovascular techniques such ...
Cached Medicine News:Health News:New Colon Cancer Test Might Spot Trouble Earlier 2Health News:New Colon Cancer Test Might Spot Trouble Earlier 3Health News:ZYTO Corp. Appoints New Chief Operations Officer and New Chief Financial Officer 2Health News:InterMune to Present at the 2008 Wachovia Healthcare Conference 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Peripheral Arterial Disease Costlier to Treat Than Heart Trouble 2
Inquire...
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Sterilization: sterilized Yes...
Effective adhesive, may be removed from plate without residue. Transparent film for easy visual monitoring of samples...
Medicine Products: